Compare
Aurinia Pharmaceuticals Inc. vs Cryoport, Inc. vs Vera Therapeutics, Inc. vs Arvinas, Inc.
| Latest fiscal year | Aurinia Pharmaceuticals Inc. AUPHRevenue covers only part of its income (partial revenue) | Cryoport, Inc. CYRX | Vera Therapeutics, Inc. VERA | Arvinas, Inc. ARVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $176.18M | n/a | $262.60M |
| Revenue growth (YoY) | n/a | +12.4% | n/a | -0.3% |
| Gross margin | n/a | 47.1% | n/a | n/a |
| Operating margin | n/a | -20.9% | n/a | -45.1% |
| Net margin | n/a | 44.4% | n/a | -30.8% |
| Net income | $287.20M | $78.30M | -$299.62M | -$80.80M |
| EPS (Diluted) | $2.07 | $1.40 | -$4.66 | -$1.14 |
| Operating cash flow | $135.66M | -$8.58M | -$241.10M | -$273.80M |
| Free cash flow | n/a | -$25.02M | -$241.73M | -$275.70M |
| Cash & equivalents | $80.16M | $250.49M | $354.73M | $142.90M |
| Total assets | $751.59M | $764.99M | $734.73M | $717.90M |
| Total liabilities | $170.26M | $262.35M | $130.21M | $284.00M |
| Shareholders' equity | $581.33M | $502.64M | $604.52M | $433.90M |
| Return on year-end equity | 49.4% | 15.6% | -49.6% | -18.6% |
| Shares outstanding | 132.32M | 49.85M | n/a | 63.50M |
Revenue, most recent five fiscal years
| Fiscal year | Aurinia Pharmaceuticals Inc. | Cryoport, Inc. | Vera Therapeutics, Inc. | Arvinas, Inc. |
|---|---|---|---|---|
| Latest | n/a | $176.18M Ended 2025-12-31 | n/a | $262.60M Ended 2025-12-31 |
| 1 year earlier | n/a | $156.77M Ended 2024-12-31 | n/a | $263.40M Ended 2024-12-31 |
| 2 years earlier | n/a | $168.66M Ended 2023-12-31 | n/a | $78.50M Ended 2023-12-31 |
| 3 years earlier | n/a | $237.28M Ended 2022-12-31 | n/a | $131.40M Ended 2022-12-31 |
| 4 years earlier | n/a | $222.61M Ended 2021-12-31 | n/a | $53.60M Ended 2021-12-31 |